Recruiting

Testing a new immune-boosting combination for advanced cancers

Plain-English translation of NCT05483400 on ClinicalTrials.gov ↗ · Source last updated March 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination of two medications called atezolizumab and tiragolumab to see if they work better together against certain cancers. The research focuses on head and neck cancer, melanoma, and a type of colorectal cancer with specific genetic changes. The medication works by helping your immune system recognize and fight cancer cells more effectively.

While single immune-boosting treatments help some patients, not everyone responds, and researchers want to find more effective combinations. This trial explores whether the new treatment combination can help more patients while keeping side effects manageable.

Do you qualify?

You likely qualify if…

you have been diagnosed with localized head and neck cancer, advanced melanoma that didn't respond to prior immune treatment, or advanced colorectal cancer with specific genetic changes
you are age 18 or older
your overall health is good enough to tolerate treatment (an ECOG performance status of 0 or 1, meaning you can do most of your normal activities)
you have measurable cancer on imaging scans
your blood counts, kidney function, and liver function are adequate based on blood tests
you can commit to following the study protocol and using effective contraception if you could become pregnant

You likely don't qualify if…

you have had a prior immune checkpoint inhibitor treatment (such as anti-PD-1 or anti-PD-L1 medications) — unless you are in the melanoma group specifically
you have an active infection or signs of infection within 2 weeks before starting treatment
you are pregnant or breastfeeding
you have a history of severe allergic reactions to similar types of antibody medications
you are HIV-positive or have active hepatitis B

What participation looks like

You would receive intravenous infusions of the two medications every three weeks at a hospital or clinic. For head and neck cancer patients, you would receive treatment for a period of time before undergoing surgery to remove the tumor. The study involves blood tests, imaging scans, and a biopsy of your tumor to help researchers understand how the medications work. Your doctors will monitor you closely for side effects and how well the treatment is working.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(1 site)

Netherlands

University Medical Center Groningen, Groningen